Immunogenicity of Adjuvanted or Non-adjuvanted H5N1 Booster Vaccine in Adults Primed to A/VN/1194/04

Phase 1

Completed

• Conditions: Influenza
• Interventions: Biological: Aflunov (single prime, single boost); Biological: Aflunov (double prime, single boost); Biological: Aflunov (No prime, single boost)

• Registration Number: NCT00814385
• Lead Sponsor: University Hospitals, Leicester

Brief Summary

This study focuses on pre-pandemic priming of man against H5 influenza with the goal of mounting a robust antibody response to small quantities of vaccine either before or during an H5 pandemic.

Detailed Description

OBJECTIVES:

Immunogenicity objectives

1. To evaluate the magnitude of the antibody responses to one or two 'priming' 0.5mL intramuscular (IM) doses of an MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) influenza vaccine, each dose containing 7.5μg of H5N1 haemagglutinin, in immunologically naïve subjects;

2. To examine the kinetics of the antibody responses to one 0.5mL 'booster' intramuscular dose of antigenically drifted MF59-adjuvanted vaccine, or non-adjuvanted antigenically drifted vaccine, given at doses of 3.75 or 7.5μg, in subjects primed with one or two doses of an MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) influenza vaccine;

3. To evaluate the magnitude of the antibody responses to one 0.5mL 'booster' intramuscular dose of antigenically drifted MF59-adjuvanted vaccine, or non-adjuvanted antigenically drifted vaccine, given at doses of 3.75μg or 7.5μg, in subjects primed with one or two doses of an MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) influenza vaccine;

4. To evaluate the breadth of the antibody responses induced by 'priming' (see 1., above), and 'booster' vaccination regimens (see 2., and 3., above), with respect to a representative range of antigenically distinct H5N1 viruses (wild-type and attenuated); and

5. To evaluate the persistence of the antibody responses induced by 'priming' (see 1., above), and 'booster' vaccination regimens (see 2., and 3., above).

Safety objective

1. To evaluate the safety of the administration of one or two 'priming' 0.5mL intramuscular (IM) doses of an MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) influenza vaccine (each dose containing 7.5μg of H5N1 haemagglutinin), in immunologically naïve subjects, followed by one 3.75μg or 7.5μg 'booster' dose of antigenically drifted MF59-adjuvanted H5N1 vaccine, or non-adjuvanted antigenically drifted H5N1 vaccine.

Study Timeline

• Study Start: 2008-11
• Study First Submitted: 2008-12-23
• Study First Submitted QC: 2008-12-23
• Study First Posted: 2008-12-24
• Primary Completion: 2013-09
• Study Completion: 2013-12
• Status Verified: 2014-06
• Last Update Submitted: 2014-06-02
• Last Update Posted: 2014-06-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 606

Inclusion Criteria

1. Subjects 18 to 59 years of age, or 60 years of age and older, mentally competent, who have signed an informed consent form after having received a detailed explanation of the study protocol;

2. Are in good health or have one or more stable (See footnote) medical conditions, as determined by:

   1. Medical history,
   2. Physical examination,
   3. Clinical judgment of the medical investigator;

3. Are able to understand and comply with all study procedures and to complete study diaries, can be contacted, and will be available for study visits.

4. Subjects who experienced fever (defined as axillary temperature >38oC) within 3 days prior to Visit 1;

5. Subjects who are pregnant or breastfeeding;

6. Females of childbearing potential who refuse to use an acceptable method of birth control for a period of 56 days before and after each vaccination. Adequate contraception is defined as hormonal (e.g., oral, injection, transdermal patch, implant, cervical ring), barrier (e.g., condom with spermicide or diaphragm with spermicide), intrauterine device (e.g., IUD), monogamous relationship with vasectomised partner who has been vasectomised for 6 months or more prior to the subject's study entry, or abstain from heterosexual intercourse (e.g., through sexual orientation or religious or other beliefs about premarital intercourse);

7. Subjects with any serious disease, including:

   1. cancer,
   2. acute or progressive hepatic disease,
   3. acute or progressive renal disease,
   4. chronic pulmonary disease requiring home oxygen therapy,
   5. active neurological disorder,
   6. autoimmune disease (including rheumatoid arthritis);

8. Subjects for whom surgery is planned during the study period;

9. Subjects with a bleeding diathesis;

10. Subjects with hypersensitivity to eggs, chicken protein, chicken feathers, influenza viral protein, neomycin or kanamycin, or any other component of the study vaccine;

11. Subjects with a history of any neurological symptoms and signs, or anaphylactic shock following administration of any vaccine;

12. Subjects with known or suspected impairment/alteration of immune function, for example, resulting from:

    1. receipt of oral immunosuppressive therapy (e.g., corticosteroid therapy or cancer chemotherapy) (long-term, inhaled steroids for asthma management is acceptable),
    2. receipt of immunostimulants or interferon,
    3. receipt of parenteral immunoglobulin preparation, blood products, and/or plasma derivatives within 3 months prior to Visits 1 (Day 1), 2 (Day 22), or 5 (Day 382), or planned during the full length of the study,
    4. high risk from developing an immunocompromising disease;

13. Actual or planned receipt of another vaccine during the period 3 weeks before to 3 weeks after vaccination on Days 1, 22, and 382;

14. Subjects with a history of (or current) drug or alcohol abuse (20g/day for females; 30g/day for males) that in the investigator's opinion would interfere with safety of the subject or the evaluation of the study objectives;

15. Subjects who are unable to lead an independent life either physically or mentally;

16. Have participated in a previous study of H5 avian influenza vaccine;

17. Have been previously vaccinated with a vaccine containing MF59 or similar adjuvant;

18. Subjects with any condition, which, in the opinion of the Investigator, might interfere with the evaluation of the study objectives.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Vaccine arm 1	Aflunov (single prime, single boost)	Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
Vaccine arm 2	Aflunov (single prime, single boost)	Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
Vaccine arm 5	Aflunov (double prime, single boost)	Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
vaccine arm 6	Aflunov (double prime, single boost)	Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 3.75microg dose at 52 weeks
Vaccine arm 3	Aflunov (single prime, single boost)	Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
Vaccine arm 4	Aflunov (single prime, single boost)	Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin, given as single dose followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
Vaccine arm 7	Aflunov (double prime, single boost)	Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by non-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
Vaccine arm 8	Aflunov (double prime, single boost)	Two doses of Mf59-adjuvanted A/VN/1194/04 H5N1 vaccine containing 7.5microg haemagglutinin followed by MF59-adjuvanted H5N1 clade 2 vaccine containing 7.5microg dose at 52 weeks
Vaccine arm 9	Aflunov (No prime, single boost)	No priming dose and single dose MF59 adjuvanted H5N1 vaccine at 52 weeks

Primary Outcome Measures

Name	Time	Method
Geometric mean antibody titres to influenza H5N1 by neutralising antibody, HI and SRH	pre vaccination, 3 weeks, 6 weeks, 52 weeks, 55 weeks, 56 weeks

Secondary Outcome Measures

Name	Time	Method
local and systemic reactogenicity	within 7 days of each vaccination
Seroprotective and seroconversion responses to H5N1 by neutralising antibody, HI and SRH	Prevaccination, 3 weeks, 6 weeks, 52 weeks, 55 weeks and 56 weeks

Trial Locations

Locations (2)

Clincal Trials Unit Leicester Royal Infirmary; 🇬🇧 Leicester, United Kingdom

University Hospitals Leicester; 🇬🇧 Leicester, Leicestershire, United Kingdom